These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

587 related articles for article (PubMed ID: 27655102)

  • 1. B Cell-Activating Factor (BAFF)-Targeted B Cell Therapies in Inflammatory Bowel Diseases.
    Uzzan M; Colombel JF; Cerutti A; Treton X; Mehandru S
    Dig Dis Sci; 2016 Dec; 61(12):3407-3424. PubMed ID: 27655102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents.
    Lenert A; Lenert P
    Drug Des Devel Ther; 2015; 9():333-47. PubMed ID: 25609919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aging murine B cells have decreased class switch induced by anti-CD40 or BAFF.
    Frasca D; Riley RL; Blomberg BB
    Exp Gerontol; 2007 Mar; 42(3):192-203. PubMed ID: 17067770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Role of B-cell-activating-factor in immune regulation--review].
    Du JF; Wang JX; Xu DG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Jun; 14(3):631-4. PubMed ID: 16800959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BAFF, APRIL and human B cell disorders.
    Tangye SG; Bryant VL; Cuss AK; Good KL
    Semin Immunol; 2006 Oct; 18(5):305-17. PubMed ID: 16916610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fingolimod induces BAFF and expands circulating transitional B cells without activating memory B cells and plasma cells in multiple sclerosis.
    Miyazaki Y; Niino M; Takahashi E; Suzuki M; Mizuno M; Hisahara S; Fukazawa T; Amino I; Nakano F; Nakamura M; Akimoto S; Minami N; Fujiki N; Doi S; Shimohama S; Terayama Y; Kikuchi S
    Clin Immunol; 2018 Feb; 187():95-101. PubMed ID: 29079163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD40- and CD95-specific antibody single chain-Baff fusion proteins display BaffR-, TACI- and BCMA-restricted agonism.
    Nelke J; Medler J; Weisenberger D; Beilhack A; Wajant H
    MAbs; 2020; 12(1):1807721. PubMed ID: 32840410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers.
    Wong DP; Roy NK; Zhang K; Anukanth A; Asthana A; Shirkey-Son NJ; Dunmire S; Jones BJ; Lahr WS; Webber BR; Moriarity BS; Caimi P; Parameswaran R
    Nat Commun; 2022 Jan; 13(1):217. PubMed ID: 35017485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B cell activating factor (BAFF) and BAFF receptors: fakes and facts.
    Ferraccioli G; Gremese E
    Clin Exp Immunol; 2017 Dec; 190(3):291-292. PubMed ID: 28834574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of the BAFF/APRIL system on T cell function.
    Mackay F; Leung H
    Semin Immunol; 2006 Oct; 18(5):284-9. PubMed ID: 16931039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of APRIL - A proliferation inducing ligand - In autoimmune diseases and expectations from its targeting.
    Baert L; Manfroi B; Casez O; Sturm N; Huard B
    J Autoimmun; 2018 Dec; 95():179-190. PubMed ID: 30385081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B cell phenotypes in patients with rheumatoid arthritis relapsing after rituximab: expression of B cell-activating factor-binding receptors on B cell subsets.
    Becerra E; De La Torre I; Leandro MJ; Cambridge G
    Clin Exp Immunol; 2017 Dec; 190(3):372-383. PubMed ID: 28800164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mouse model of systemic lupus erythematosus responds better to soluble TACI than to soluble BAFFR, correlating with depletion of plasma cells.
    Haselmayer P; Vigolo M; Nys J; Schneider P; Hess H
    Eur J Immunol; 2017 Jun; 47(6):1075-1085. PubMed ID: 28383107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting T and B lymphocytes in inflammatory bowel diseases: lessons from clinical trials.
    Gerner RR; Moschen AR; Tilg H
    Dig Dis; 2013; 31(3-4):328-35. PubMed ID: 24246983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BAFF, APRIL and their receptors: structure, function and signaling.
    Bossen C; Schneider P
    Semin Immunol; 2006 Oct; 18(5):263-75. PubMed ID: 16914324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Modulating the survival and maturation system of B lymphocytes: Current and future new therapeutic strategies in systemic lupus erythematosus].
    Valor L; López-Longo FJ
    Med Clin (Barc); 2015 Sep; 145(5):206-10. PubMed ID: 25433780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production.
    Lavie F; Miceli-Richard C; Ittah M; Sellam J; Gottenberg JE; Mariette X
    Ann Rheum Dis; 2007 May; 66(5):700-3. PubMed ID: 17040963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Research advances on B-cell activating factor and its targeted agents in inflammatory bowel disease].
    Li L; Liu HY; Wang LJ
    Zhongguo Dang Dai Er Ke Za Zhi; 2024 Mar; 26(3):315-320. PubMed ID: 38557386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B-cell-targeted therapy for systemic lupus erythematosus.
    Sabahi R; Anolik JH
    Drugs; 2006; 66(15):1933-48. PubMed ID: 17100405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Recombinant proteins or monoclonal antibodies: comparative properties and interest in systemic lupus erythematosus].
    Terrier B; Mouthon L
    Med Sci (Paris); 2013 Jan; 29(1):65-73. PubMed ID: 23351696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.